Contact Supplier

Contact Supplier

To get in touch with TAmiRNA GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    TAmiRNA offers hepatomiR® RUO RT-qPCR test kit for novel liver function biomarkers

    products-servicesTAmiRNA GmbH
    February 3rd 2022

    Diagnostic innovator TAmiRNA has developed the microRNA-based hepatomiR® research-use only (RUO) test kit to meet the urgent need for standardized analysis of three novel microRNA liver biomarkers.

    The new kit now provides a highly sensitive and specific RT-qPCR test and software application to obtain high quality results for the analysis of these blood-based biomarkers to assess liver function.

    hepatomiR® kit features

    TAmiRNA’s hepatomiR® kit is designed for high throughput allowing analysis of up to 12 samples per 96-well or 48 samples per 384-well plate.

    The hepatomiR® microRNA panel enables quantitative analysis of three liver-enriched microRNAs hsa-miR-122-5p, hsa-miR- 192-5p, and hsa-miR-151a-5p in plasma samples.

    The test is effective on sample volumes as low as 200 µL of platelet-poor plasma, with even lower volumes usable for research (RUO) purposes. Samples can be deep-frozen (-70°C or lower) or fresh (centrifuge plasma within 2 hours of blood collection).

    The kit is designed for ease of use and efficiency, using primer-coated 96- or 384-well plates to minimize hands-on time and technical variability.

    Fast and simple data analysis is provided by the associated hepatomiR® software application, which can speed analysis time from raw data to final results in under five minutes and converts raw miRNA levels into normalized values and even computes a combined liver function score. This score is currently under clinical investigation for the prediction of postoperative liver dysfunction in liver cancer patients.

    hepatomiR® kit advantages

    Apart from providing a highly sensitive and specific blood-based biomarker to assess liver function, the new hepatomiR® kit offers several other valuable advantages, and has thus great application potential.

    • as a potential surrogate marker for hepatic vein pressure gradient, and
    • for the prognosis, diagnosis, staging, monitoring and treatment response of chronic or acute liver and metabolic diseases, like
      • Drug-induced liver injury
      • AFLD, NAFLD and NASH
      • Other chronic liver diseases
      • Cardiometabolic syndrome and type-2 diabetes

    The hepatomiR® assay enables quantification of 3 liver-informative microRNAs, including the established liver function biomarker miR-122, which is:

    • at least as informative as alanine aminotransferase (ALT) in acetaminophen (APAP)-induced liver injury.
    • useful to discriminate between hepatic and non-hepatic serum ALT elevations, such as muscular toxicity, with pre-clinical data suggesting serum levels of miR-122 increase earlier than ALT levels;
    • significantly increased in acute liver injury (ALI) patients but not chronic kidney disease (CKD) patients.


    Click on TAmiRNA hepatomiR® as innovative blood-based liver biomarker  for further information.


    hepatomiR® is a blood-based Biomaker for the Assessment of Live Function before Hepatectomy in patients with HCC, CCC or mCRC

    TAmiRNA offers hepatomiR® RUO RT-qPCR test kit for novel liver function biomarkers

    Contact TAmiRNA GmbH

    Simply fill out the form below to contact TAmiRNA GmbH now.

    Send TAmiRNA GmbH a Message